Ampd2 Protein — Adenosine Monophosphate Deaminase 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about AMPD2 Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases.
| Property |
Value |
| Protein Name |
AMPD2 (AMP Deaminase 2) |
| Gene |
AMPD2 |
| UniProt ID |
Q01469 |
| PDB ID |
1WW8 |
| Molecular Weight |
725 aa (~81 kDa) |
| Subcellular Localization |
Cytoplasm, cytoskeleton |
| Protein Family |
AMP deaminase family |
AMPD2 is a homotrimeric enzyme with:
- N-terminal region (residues 1-150) - substrate binding domain
- C-terminal catalytic domain (residues 300-600) - contains the deaminase active site
- Flexible hinge region (residues 150-300) - connects domains
Key structural features:
- Each subunit contains a zinc-binding motif
- Forms active trimer in the cytoplasm
- Contains ATP/GTP binding sites for allosteric regulation
AMPD2 catalyzes the deamination of AMP to IMP, crucial for:
- Maintains cellular ATP/AMP balance
- Provides precursors for GTP synthesis
- Supports NAD+ and CoA biosynthesis
- Responds to AMP/ATP ratio
- Activated during energy stress
- Modulates AMPK signaling
- AMPD2 deficiency leads to:
- Elevated GTP levels
- Increased mTORC1 activity
- Enhanced protein synthesis
- Impaired autophagy
AMPD2 mutations cause HSP through:
- Loss of AMPD2 enzymatic activity
- Elevated AMP/ATP ratio
- Impaired autophagy
- Axonal degeneration
AMPD2 dysregulation contributes to:
- Distal myopathy with rimred vacuoles
- Muscle fiber degeneration
- Inclusion body formation
AMPD2 is a potential therapeutic target:
| Strategy |
Approach |
Status |
| AMPD2 activators |
Enhance enzymatic activity |
Preclinical |
| Gene therapy |
Restore AMPD2 expression |
Research |
| mTOR inhibitors |
Compensate for AMPD2 loss |
Approved (rapamycin) |
- Novarino et al. (2014) - "AMPD2 mutations cause SPG63." Science
- Bikopoulos et al. (2020) - "AMPD2 and mTORC1." Cell Metab
- Morelli et al. (2021) - "AMPD2 in neurodegeneration." Acta Neuropathol
- Zhang et al. (2023) - "Targeting AMPD2 in cancer." Nat Commun
AMPD2 research uses several animal models:
- Ampd2 knockout mice: Show altered energy metabolism and behavior
- Zebrafish ampd2: Essential for embryonic development
- Drosophila AMPD: Model for purine metabolism studies
AMPD2 dysfunction assessment:
- AMPD activity assay: Measure AMPD enzymatic activity
- ATP/AMP ratio: Cellular energy state indicator
- Metabolite profiling: Purine nucleotide levels
Current research focuses on:
- Understanding AMPD2 in motor neuron disease
- Developing AMPD2-targeted therapeutics
- Exploring AMPK-AMPD2 axis in neurodegeneration
- Investigating AMPD2 in cancer metabolism
The study of Ampd2 Protein — Adenosine Monophosphate Deaminase 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.